cetuximab,pembrolizumab
merck,eli lilly
[]
. s dr. patrick boland ( ) &amp; colleagues present molecular characterization of metastatic #colorectal cancer (mcrc) in patients (pts) treated with cetuximab and pembrolizumab #gi23 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.